Company profile: Laetus
1.1 - Company Overview
Company description
- Provider of inline quality control and track & trace systems, including serialization, aggregation, and traceability, plus packaging execution systems and vision inspection solutions (ARGUS, POLYPHEM, INSPECT) to ensure packaging accuracy, product integrity verification, supply chain transparency, counterfeit protection, recall efficiency, and efficient returns.
Products and services
- Quality Control Solutions: Integrates inline vision inspection within track and trace systems to verify product integrity using ARGUS, POLYPHEM, and INSPECT
- Modular
- Serialization: Assigns unique codes to products for supply chain traceability, deters counterfeiting, and accelerates recall efficiency
- Secure
- Aggregation: Combines serialized packages into larger units with traceable relationships to strengthen counterfeit protection and enable efficient returns
- Industrial-grade.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Laetus
NiKang Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule oncology therapeutics, developing NKT2152, a HIF2α inhibitor in Phase 1/2 for clear cell renal cell carcinoma and other solid tumors; NKT3447, a reversible ATP-competitive CDK2 inhibitor in Phase 1 for solid tumors; KRAS G12D mutation inhibitors; and a SHP2 inhibitor being clinically evaluated by Erasca.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NiKang Therapeutics company profile →
Eclipse Solutions
HQ: United States
Website
- Description: Provider of clinical technology with data management, biostatistics, consulting, and certified medical and drug coding solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eclipse Solutions company profile →
System Analytic
HQ: United Kingdom
Website
- Description: Provider of an ecosystem of innovative digital tools and world-class services to support the entire KOL/HCP engagement cycle.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full System Analytic company profile →
Clinpal
HQ: United Kingdom
Website
- Description: Provider of patient-centric, cloud-enabled clinical trial solutions, including the Clinpal platform and consulting. Clinpal offers modules: Build for study configuration; Presence for patient/clinician/site engagement; Recruit for recruitment; Educate for training and eConsent; Capture for data acquisition and management; and Engage for dashboards, calendars, and reminders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clinpal company profile →
Compendia Bioscience
HQ: United States
Website
- Description: Provider of cancer genomics solutions for oncology research, including bioinformatics to prioritize and annotate driver variants and link biomarkers to curated knowledge; reporting that connects biomarkers to therapies, guidelines, and clinical trials; targeted NGS assays with PCR-based library prep; liquid biopsy tools using cfDNA/ctDNA/CTCs with digital PCR/NGS; and whole exome sequencing via Ion Proton.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Compendia Bioscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Laetus
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Laetus
2.2 - Growth funds investing in similar companies to Laetus
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Laetus
4.2 - Public trading comparable groups for Laetus
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →